Zacks Research Brokers Reduce Earnings Estimates for ENSC

Ensysce Biosciences, Inc. (NASDAQ:ENSC) – Equities researchers at Zacks Research dropped their Q3 2026 earnings per share estimates for Ensysce Biosciences in a research note issued on Friday, August 14th. Zacks Research analyst B. Sorensen now forecasts that the company will post earnings per share of ($0.19) for the quarter, down from their previous estimate of $0.04. The consensus estimate for Ensysce Biosciences’ current full-year earnings is ($1.27) per share. Zacks Research also issued estimates for Ensysce Biosciences’ Q4 2026 earnings at ($0.18) EPS, FY2026 earnings at ($1.09) EPS and FY2027 earnings at ($0.06) EPS.

Other equities research analysts have also recently issued research reports about the company. Wall Street Zen raised Ensysce Biosciences to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ensysce Biosciences in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Ensysce Biosciences Price Performance

NASDAQ:ENSC opened at $0.39 on Thursday. The company’s 50-day moving average is $0.31 and its two-hundred day moving average is $0.39. The firm has a market capitalization of $7.55 million, a price-to-earnings ratio of -0.14 and a beta of 0.84. Ensysce Biosciences has a 1-year low of $0.23 and a 1-year high of $2.75.

Ensysce Biosciences (NASDAQ:ENSC) last issued its earnings results on Thursday, August 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.20). Ensysce Biosciences had a negative return on equity of 2,550.30% and a negative net margin of 280.53%.The company had revenue of $1.16 million during the quarter, compared to analysts’ expectations of $1.20 million.

Insider Buying and Selling

In other Ensysce Biosciences news, Director Bob G. Gower purchased 400,000 shares of Ensysce Biosciences stock in a transaction that occurred on Friday, August 7th. The stock was purchased at an average price of $0.49 per share, for a total transaction of $196,000.00. Following the transaction, the director directly owned 916,740 shares in the company, valued at $449,202.60. This trade represents a 77.41% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 2.80% of the stock is currently owned by company insiders.

Institutional Trading of Ensysce Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC purchased a new stake in shares of Ensysce Biosciences during the third quarter worth approximately $34,000. Citadel Advisors LLC purchased a new position in shares of Ensysce Biosciences in the 3rd quarter valued at about $34,000. DRW Securities LLC increased its holdings in Ensysce Biosciences by 42.4% in the fourth quarter. DRW Securities LLC now owns 98,481 shares of the company’s stock valued at $91,000 after buying an additional 29,336 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its stake in Ensysce Biosciences by 100.4% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 149,711 shares of the company’s stock valued at $138,000 after purchasing an additional 75,000 shares in the last quarter. 5.63% of the stock is owned by hedge funds and other institutional investors.

About Ensysce Biosciences

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.